Literature DB >> 15801034

Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Adam Mor1, Clifton O Bingham, Clifton Bingham, Laura Barisoni, Eileen Lydon, H Michael Belmont.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15801034

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  Tumour necrosis factor alpha blockade and the risk of vasculitis.

Authors:  M De Bandt; B Saint-Marcoux
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

3.  Acute interstitial nephritis associated with etanercept.

Authors:  Toshiro Sugimoto; Mako Yasuda; Masayoshi Sakaguchi; Tetsuro Koyama; Takashi Uzu; Junichi Nishioka; Atsunori Kashiwagi
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

Review 4.  Vasculitis induced by tumor necrosis factor-targeted therapies.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

5.  Clinical and histological features of lupus nephritis induced by anti-TNFα therapy.

Authors:  Tiziana Piccolo; Piero Lisi; Enza Valicenti; Giovanni Pannarale; Pasquale Coratelli
Journal:  NDT Plus       Date:  2008-06-17

6.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06

Review 7.  The role of tumor necrosis factor-alpha in systemic lupus erythematosus.

Authors:  Martin Aringer; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2008-01-23       Impact factor: 5.156

8.  Adalimumab (TNF α Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient.

Authors:  S S Wei; R Sinniah
Journal:  Case Rep Nephrol       Date:  2013-07-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.